Alps Advisors Inc. Boosts Stake in Minerva Neurosciences Inc (NERV)

Alps Advisors Inc. lifted its holdings in Minerva Neurosciences Inc (NASDAQ:NERV) by 30.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 89,824 shares of the biopharmaceutical company’s stock after buying an additional 21,209 shares during the period. Alps Advisors Inc.’s holdings in Minerva Neurosciences were worth $605,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of NERV. Dimensional Fund Advisors LP increased its holdings in shares of Minerva Neurosciences by 302.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,572,618 shares of the biopharmaceutical company’s stock worth $19,736,000 after buying an additional 1,181,577 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Minerva Neurosciences by 12.2% in the 3rd quarter. BlackRock Inc. now owns 2,448,326 shares of the biopharmaceutical company’s stock worth $30,727,000 after buying an additional 266,623 shares during the last quarter. Marshall Wace North America L.P. increased its holdings in shares of Minerva Neurosciences by 33.2% in the 3rd quarter. Marshall Wace North America L.P. now owns 555,675 shares of the biopharmaceutical company’s stock worth $6,974,000 after buying an additional 138,475 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Minerva Neurosciences by 72.3% in the 3rd quarter. Renaissance Technologies LLC now owns 303,200 shares of the biopharmaceutical company’s stock worth $3,805,000 after buying an additional 127,200 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Minerva Neurosciences in the 3rd quarter worth about $1,510,000. Hedge funds and other institutional investors own 74.62% of the company’s stock.

A number of analysts have recently weighed in on the stock. BidaskClub downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Thursday, January 17th. Zacks Investment Research upgraded shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a report on Tuesday, February 5th. Finally, ValuEngine upgraded shares of Minerva Neurosciences from a “hold” rating to a “buy” rating in a report on Thursday, February 7th.

In related news, CFO Geoff Race sold 5,999 shares of the company’s stock in a transaction dated Monday, December 17th. The shares were sold at an average price of $7.46, for a total transaction of $44,752.54. Following the transaction, the chief financial officer now directly owns 204,369 shares in the company, valued at approximately $1,524,592.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William F. Doyle purchased 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 11th. The shares were purchased at an average price of $7.97 per share, for a total transaction of $47,820.00. Following the completion of the acquisition, the director now directly owns 16,611 shares in the company, valued at approximately $132,389.67. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 10,000 shares of company stock worth $77,220 and have sold 16,007 shares worth $120,971. Corporate insiders own 9.60% of the company’s stock.

Shares of NASDAQ:NERV opened at $7.33 on Thursday. The stock has a market cap of $288.81 million, a P/E ratio of -6.79 and a beta of 1.41. Minerva Neurosciences Inc has a 12 month low of $5.00 and a 12 month high of $12.95.

COPYRIGHT VIOLATION NOTICE: “Alps Advisors Inc. Boosts Stake in Minerva Neurosciences Inc (NERV)” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2019/02/14/alps-advisors-inc-boosts-stake-in-minerva-neurosciences-inc-nerv.html.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

See Also: How does a 12b-1 fee affect fund performance?

Want to see what other hedge funds are holding NERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerva Neurosciences Inc (NASDAQ:NERV).

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply